Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

Pharmacol Res. 2023 Oct:196:106938. doi: 10.1016/j.phrs.2023.106938. Epub 2023 Sep 23.
No abstract available

Keywords: Adalimumab; Inflammatory bowel disease; Infliximab; Pediatric; Pharmacogenetics; Polymorphism.

Publication types

  • Letter